Platelet activation in Alzheimer disease

Steven Sevush, Wenche Jy, Lawrence L. Horstman, Wei Wei Mao, Luciano Kolodny, Yeon Ahn

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Background: In light of recent reports of diminished platelet serotonin concentration and increased plasma serotonin levels in patients with Alzheimer disease (AD), we hypothesized that a state of heightened platelet activation might be present in AD. Objective: To compare baseline activation of unstimulated platelets in patients with AD with that in control subjects. Patients and Methods: Flow cytometry was used to measure platelet activation in 91 patients with probable AD and 40 age-matched control subjects. Groups were compared for percentage of circulating platelet aggregates, expression of CD62p, formation of leukocyte-platelet complexes, and presence of circulating platelet microparticles, controlling for effects of demographic, clinical, physiological, and logistical factors. Results: Multiple analysis of covariance on ranked data revealed a 39.5% increase in percentage of platelet aggregates (P=.0001), a 59.3% increase in expression of CD62p (P=.001), and a 53.3% increase in leukocyte-platelet complexes (P=.0001) in the group with AD but no differences in the number of platelet microparticles, overall platelet count, plasma fibrinogen level, or plasma platelet factor 3. Activation was weakly correlated with sex, but was independent of age, severity of disease, duration of disease, depression, agitation, and family history of dementia. Conclusions: Platelets of patients with AD exhibit greater unstimulated activation than those of controls. Potential causes of such activation include possible stimulation of platelets by damaged cerebral endothelial cells or platelet activation induced by membrane abnormalities previously reported to be present in platelets of patients with AD. In light of recent evidence that platelets are the principal source of both amyloid precursor protein and β-amyloid peptide in human blood, it is possible that AD platelet activation may reflect or even contribute to the pathogenesis of the disease.

Original languageEnglish
Pages (from-to)530-536
Number of pages7
JournalArchives of Neurology
Volume55
Issue number4
DOIs
StatePublished - Apr 1 1998

Fingerprint

Platelet Activation
Alzheimer Disease
Blood Platelets
Platelet Count
Serotonin
Leukocytes
Platelet Factor 3
Activation
Alzheimer's Disease
Amyloid beta-Protein Precursor
Amyloid
Fibrinogen
Dementia
Flow Cytometry
Endothelial Cells
Demography
Depression
Peptides
Membranes

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Sevush, S., Jy, W., Horstman, L. L., Mao, W. W., Kolodny, L., & Ahn, Y. (1998). Platelet activation in Alzheimer disease. Archives of Neurology, 55(4), 530-536. https://doi.org/10.1001/archneur.55.4.530

Platelet activation in Alzheimer disease. / Sevush, Steven; Jy, Wenche; Horstman, Lawrence L.; Mao, Wei Wei; Kolodny, Luciano; Ahn, Yeon.

In: Archives of Neurology, Vol. 55, No. 4, 01.04.1998, p. 530-536.

Research output: Contribution to journalArticle

Sevush, S, Jy, W, Horstman, LL, Mao, WW, Kolodny, L & Ahn, Y 1998, 'Platelet activation in Alzheimer disease', Archives of Neurology, vol. 55, no. 4, pp. 530-536. https://doi.org/10.1001/archneur.55.4.530
Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn Y. Platelet activation in Alzheimer disease. Archives of Neurology. 1998 Apr 1;55(4):530-536. https://doi.org/10.1001/archneur.55.4.530
Sevush, Steven ; Jy, Wenche ; Horstman, Lawrence L. ; Mao, Wei Wei ; Kolodny, Luciano ; Ahn, Yeon. / Platelet activation in Alzheimer disease. In: Archives of Neurology. 1998 ; Vol. 55, No. 4. pp. 530-536.
@article{1eeeec02250443a38d7b16bc6cfd0711,
title = "Platelet activation in Alzheimer disease",
abstract = "Background: In light of recent reports of diminished platelet serotonin concentration and increased plasma serotonin levels in patients with Alzheimer disease (AD), we hypothesized that a state of heightened platelet activation might be present in AD. Objective: To compare baseline activation of unstimulated platelets in patients with AD with that in control subjects. Patients and Methods: Flow cytometry was used to measure platelet activation in 91 patients with probable AD and 40 age-matched control subjects. Groups were compared for percentage of circulating platelet aggregates, expression of CD62p, formation of leukocyte-platelet complexes, and presence of circulating platelet microparticles, controlling for effects of demographic, clinical, physiological, and logistical factors. Results: Multiple analysis of covariance on ranked data revealed a 39.5{\%} increase in percentage of platelet aggregates (P=.0001), a 59.3{\%} increase in expression of CD62p (P=.001), and a 53.3{\%} increase in leukocyte-platelet complexes (P=.0001) in the group with AD but no differences in the number of platelet microparticles, overall platelet count, plasma fibrinogen level, or plasma platelet factor 3. Activation was weakly correlated with sex, but was independent of age, severity of disease, duration of disease, depression, agitation, and family history of dementia. Conclusions: Platelets of patients with AD exhibit greater unstimulated activation than those of controls. Potential causes of such activation include possible stimulation of platelets by damaged cerebral endothelial cells or platelet activation induced by membrane abnormalities previously reported to be present in platelets of patients with AD. In light of recent evidence that platelets are the principal source of both amyloid precursor protein and β-amyloid peptide in human blood, it is possible that AD platelet activation may reflect or even contribute to the pathogenesis of the disease.",
author = "Steven Sevush and Wenche Jy and Horstman, {Lawrence L.} and Mao, {Wei Wei} and Luciano Kolodny and Yeon Ahn",
year = "1998",
month = "4",
day = "1",
doi = "10.1001/archneur.55.4.530",
language = "English",
volume = "55",
pages = "530--536",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Platelet activation in Alzheimer disease

AU - Sevush, Steven

AU - Jy, Wenche

AU - Horstman, Lawrence L.

AU - Mao, Wei Wei

AU - Kolodny, Luciano

AU - Ahn, Yeon

PY - 1998/4/1

Y1 - 1998/4/1

N2 - Background: In light of recent reports of diminished platelet serotonin concentration and increased plasma serotonin levels in patients with Alzheimer disease (AD), we hypothesized that a state of heightened platelet activation might be present in AD. Objective: To compare baseline activation of unstimulated platelets in patients with AD with that in control subjects. Patients and Methods: Flow cytometry was used to measure platelet activation in 91 patients with probable AD and 40 age-matched control subjects. Groups were compared for percentage of circulating platelet aggregates, expression of CD62p, formation of leukocyte-platelet complexes, and presence of circulating platelet microparticles, controlling for effects of demographic, clinical, physiological, and logistical factors. Results: Multiple analysis of covariance on ranked data revealed a 39.5% increase in percentage of platelet aggregates (P=.0001), a 59.3% increase in expression of CD62p (P=.001), and a 53.3% increase in leukocyte-platelet complexes (P=.0001) in the group with AD but no differences in the number of platelet microparticles, overall platelet count, plasma fibrinogen level, or plasma platelet factor 3. Activation was weakly correlated with sex, but was independent of age, severity of disease, duration of disease, depression, agitation, and family history of dementia. Conclusions: Platelets of patients with AD exhibit greater unstimulated activation than those of controls. Potential causes of such activation include possible stimulation of platelets by damaged cerebral endothelial cells or platelet activation induced by membrane abnormalities previously reported to be present in platelets of patients with AD. In light of recent evidence that platelets are the principal source of both amyloid precursor protein and β-amyloid peptide in human blood, it is possible that AD platelet activation may reflect or even contribute to the pathogenesis of the disease.

AB - Background: In light of recent reports of diminished platelet serotonin concentration and increased plasma serotonin levels in patients with Alzheimer disease (AD), we hypothesized that a state of heightened platelet activation might be present in AD. Objective: To compare baseline activation of unstimulated platelets in patients with AD with that in control subjects. Patients and Methods: Flow cytometry was used to measure platelet activation in 91 patients with probable AD and 40 age-matched control subjects. Groups were compared for percentage of circulating platelet aggregates, expression of CD62p, formation of leukocyte-platelet complexes, and presence of circulating platelet microparticles, controlling for effects of demographic, clinical, physiological, and logistical factors. Results: Multiple analysis of covariance on ranked data revealed a 39.5% increase in percentage of platelet aggregates (P=.0001), a 59.3% increase in expression of CD62p (P=.001), and a 53.3% increase in leukocyte-platelet complexes (P=.0001) in the group with AD but no differences in the number of platelet microparticles, overall platelet count, plasma fibrinogen level, or plasma platelet factor 3. Activation was weakly correlated with sex, but was independent of age, severity of disease, duration of disease, depression, agitation, and family history of dementia. Conclusions: Platelets of patients with AD exhibit greater unstimulated activation than those of controls. Potential causes of such activation include possible stimulation of platelets by damaged cerebral endothelial cells or platelet activation induced by membrane abnormalities previously reported to be present in platelets of patients with AD. In light of recent evidence that platelets are the principal source of both amyloid precursor protein and β-amyloid peptide in human blood, it is possible that AD platelet activation may reflect or even contribute to the pathogenesis of the disease.

UR - http://www.scopus.com/inward/record.url?scp=0031895587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031895587&partnerID=8YFLogxK

U2 - 10.1001/archneur.55.4.530

DO - 10.1001/archneur.55.4.530

M3 - Article

VL - 55

SP - 530

EP - 536

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 4

ER -